Drug Trial Radar · NCT01254604
Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002)
Last checked: Nov 20, 2026Latest source record: Sep 20, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
190
Actual
Start
Dec 1, 2011
Primary completion
May 9, 2013
Study completion May 9, 2013
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Dec 6, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will test the hypothesis that preservative-free tafluprost (MK-2452) is non-inferior to preservative-free timolol maleate with respect to the diurnal intraocular pressure (IOP) change from baseline after 4 weeks of therapy in participants with open-angle glaucoma or ocular hypertension.
Conditions
- Glaucoma
- Ocular Hypertension
Interventions
Preservative-Free Tafluprost or vehicleDrug
Preservative-free tafluprost (0.0015%) ophthalmic solution; Preservative-free vehicle ophthalmic solution (contains no active drug)
Preservative-Free Timolol maleateDrug
Preservative-free timolol maleate (0.5%) ophthalmic solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Diurnal IOP Change From Baseline at Week 4 - Study EyeTime frame: Baseline and Week 4
- Number of Participants With an Adverse Event (AE)Time frame: Up to 14 days after Week 4 visit
- Number of Participants Who Discontinued Study Drug Due to an AETime frame: Up to Week 4
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.